Eisai-Biogen Alzheimer's drug backed for full U.S. approval
FDA decision on Leqembi expected by July 6
Japanese drugmaker Eisai and American partner Biogen hope that their Alzheimer's disease treatment will receive formal approval from the U.S. Food and Drug Administration soon. (Photo by Kosaku Mimura)
NORIYUKI TAKADA and KAORI YOSHIDA, Nikkei staff writers | U.S.
TOKYO/NEW YORK -- An advisory panel under the U.S. Food and Drug Administration on Friday paved the way for the full approval of lecanemab, an Alzheimer's disease treatment developed by Japanese drugmaker Eisai and American partner Biogen.
The FDA had already given the drug a provisional green light in January under its Accelerated Approval pathway.